Literature DB >> 11000649

Clinical features and treatment of peristomal pyoderma gangrenosum.

A P Hughes1, J M Jackson, J P Callen.   

Abstract

CONTEXT: Peristomal pyoderma gangrenosum (PPG), an unusual variant of pyoderma gangrenosum, has been reported almost exclusively in patients with inflammatory bowel disease (IBD) and is frequently misdiagnosed.
OBJECTIVE: To better characterize the clinical manifestations, diagnosis, and management of PPG. DESIGN, SETTING, AND PATIENTS: Retrospective analysis of 7 patients with PPG observed in a university-affiliated community setting between 1988 and December 1999. MAIN OUTCOME MEASURES: Clinical and histopathologic features, associated disorders, and microbiologic findings.
RESULTS: Two patients had Crohn disease, 2 had ulcerative colitis, and 3 had abdominal cancer. Five patients had at least 1 relapse of PPG after initial healing. Although 3 of 4 patients with IBD had active bowel disease, a parallel course with PPG occurred in only 1 patient. Both patients whose stoma was relocated developed an ulcer at the new site. Effective therapies included topical superpotent corticosteroids; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cromolyn sodium; oral dapsone, prednisone, cyclosporine, mycophenolate mofetil; and intravenous infliximab.
CONCLUSION: Our experiences demonstrate that although PPG has been most often reported in patients with IBD, it may occur in the absence of IBD. Biopsy of the skin lesion is not diagnostic but excludes other causes. Relocation of the stoma may be associated with a new ulceration and should be avoided. Trauma to the skin of a predisposed patient may elicit the pustules or ulcerations associated with pathergy. JAMA. 2000;284:1546-1548.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000649     DOI: 10.1001/jama.284.12.1546

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  23 in total

1.  Ulcerative skin lesions in a child with colitis ulcerosa after colectomy.

Authors:  Leonarda Maria van Zitteren; H Jorn Bovenschen; Walter E Tjon A Ten
Journal:  BMJ Case Rep       Date:  2011-12-02

Review 2.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

Review 3.  Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases.

Authors:  Klaus Eisendle; Tobias Thuile; Jenny Deluca; Maria Pichler
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-04-28       Impact factor: 4.730

Review 4.  Diagnosis and treatment of pyoderma gangrenosum.

Authors:  Trevor Brooklyn; Giles Dunnill; Chris Probert
Journal:  BMJ       Date:  2006-07-22

Review 5.  A novel topical therapy for resistant and early peristomal pyoderma gangrenosum.

Authors:  Wendy A Pearson; David A Prentice; Deborah L Sinclair; Lee Y Lim; Keryln J Carville
Journal:  Int Wound J       Date:  2019-07-12       Impact factor: 3.315

Review 6.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

Review 7.  Cutaneous manifestation of gastrointestinal disease.

Authors:  Maral Rahvar; Justin Kerstetter
Journal:  J Gastrointest Oncol       Date:  2016-04

Review 8.  Important cutaneous manifestations of inflammatory bowel disease.

Authors:  L B Trost; J K McDonnell
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

9.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

10.  Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.

Authors:  Mark S Sapienza; Sidney Cohen; Anthony J Dimarino
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.